Table 1 Selinexor (KPT-330) in clinical trials
From: Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
Diseases | Trial | Recruting status | NCT number |
|---|---|---|---|
Relapsed ALL and AML | Phase I | Recruiting | NCT02091245 |
Unresectable melanoma | Phase I | Not yet Recruiting | NCT02120222 |
Gynaecologic malignancies | Phase II | Recruiting | NCT02025985 |
Advanced/metastatic solid tumors | Phase I | Recruiting | NCT02078349 |
Soft-tissue or bone sarcoma | Phase Ib | Recruiting | NCT01896505 |
Advanced/metastatic solid tumors | Phase I | Recruiting | NCT01607905 |
Metastatic resistant prostate cancer | Phase II | Recruiting | NCT02146833 |
Advanced hematological malignancies | Phase I | Recruiting | NCT01607892 |
Recurrent glioblastoma | Phase II | Recruiting | NCT01986348 |
Relapsed/refractory AML | Phase II | Rectruiting | NCT02088541 |
Refractory/relapsed CLL | Phase II | Recruiting | NCT02138786 |
Acute myeloid leukemia | Phase I | Recruiting | NCT02093403 |
Locally advanced rectal cancer | Phase I | Not yet Recruiting | NCT02137356 |